Maze Therapeutics (NASDAQ:MAZE) CMO Sells $1,513,500.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 30,000 shares of the stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Harold Bernstein also recently made the following trade(s):

• On Monday, February 2nd, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $46.02, for a total transaction of $690,300.00.
• On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.20, for a total transaction of $1,011,271.20.
• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.00, for a total transaction of $16,480.00.
• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.43, for a total value of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $50.21 on Friday. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $52.86. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of -2.40 and a beta of 4.47. The business has a 50 day simple moving average of $44.82 and a 200 day simple moving average of $35.75.

Analysts Set New Price Targets

Several research firms have recently issued reports on MAZE. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim lifted their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective for the company. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Finally, HC Wainwright reissued a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $54.63.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period. California State Teachers Retirement System lifted its holdings in shares of Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its stake in Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock valued at $247,000 after buying an additional 931 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Maze Therapeutics during the fourth quarter valued at about $39,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.